tech
April 2, 2026
It’s not easy to get depression-detecting AI through the FDA
Posts from this topic will be added to your daily email digest and your homepage feed.
TL;DR
- Kintsugi, a mental health startup, is closing down after its AI, designed to detect depression and anxiety from speech, did not receive FDA clearance.
- The company is releasing most of its technology as open-source, with potential applications beyond healthcare, such as detecting deepfake audio.
- The AI analyzed speech patterns to identify mental health indicators, aiming to complement or offer an alternative to traditional screening methods like questionnaires.
- Kintsugi faced difficulties navigating the FDA's De Novo pathway, which is challenging for AI systems that require continuous updates.
- Funding challenges, exacerbated by the lengthy regulatory process and a lack of further investment, led to the startup's closure.
- While open-sourcing raises concerns about misuse, the founder believes underuse is a more realistic risk.
- A portion of Kintsugi's technology, specifically tools for detecting synthetic or manipulated voices, remains private due to security concerns.
Continue reading the original article